Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01848184 · ClinicalTrials.gov registry record
A Prospective Study in Patients Undergoing Primary Ventral Hernia Repair Using Parietex™ Composite Ventral Patch
A clinical trial, sponsored by Medtronic - MITG.
- Completed
- Registry status
- 126
- Enrollment target
NCT01848184: Completed study, sponsored by Medtronic - MITG.
NCT01848184 is a clinical trial that has completed, run by Medtronic - MITG. The registered enrollment target is 126 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01848184 has completed, sponsored by Medtronic - MITG.
- COMPLETED
- Registry status
- 126 participants
- Enrollment target
Study Summary
The objective of this study is to assess the recurrence rate following the use of PARIETEX™ Composite Ventral Patch in primary ventral hernia repair by open approach with intra-peritoneal positioning.
Primary Outcome
The number of participants with hernia recurrence at 24 months, assessed during a physical examination and by ultrasonography.
Interventions
- DEVICE PARIETEX™ Composite Ventral Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2013-05 |
| Est. Completion | 2016-07 |
What the finished NCT01848184 record still lists
NCT01848184 is an observational study that tracks outcomes without assigning an intervention. The registered 126 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which PARIETEX™ Composite Ventral Patch is the first listed.
NCT01848184 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01848184 about?
NCT01848184 is a clinical study titled "A Prospective Study in Patients Undergoing Primary Ventral Hernia Repair Using Parietex™ Composite Ventral Patch". The objective of this study is to assess the recurrence rate following the use of PARIETEX™ Composite Ventral Patch in primary ventral hernia repair by open approach with intra-peritoneal positioning.
What is the current status of trial NCT01848184?
This trial is currently completed. The enrollment target is 126 participants. The study started on 2013-05. Estimated completion is 2016-07.
What interventions are being tested in trial NCT01848184?
The interventions under investigation include: PARIETEX™ Composite Ventral Patch (DEVICE).
Who is sponsoring clinical trial NCT01848184?
This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01873131 · 126 participants · NA
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
- NCT02621645 · 126 participants · Phase 4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
- NCT03838107 · 126 participants
Markers of Trajectory in Pediatric CRPS
- NCT03906422 · 126 participants · NA
Comparison of Patient-reported Pain After Initial Archwire Placement
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia